Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

by Team Lumida
June 5, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Apparel returns are surging as GLP-1 users rapidly lose weight, with one online retailer reporting a 50% increase in returns in the past year — a direct hit to gross margins that can cost a $1 billion retailer $20 million or more.
  • The share of apparel exchanges where shoppers sized down hit a record 14.6% in 2025, up for three consecutive years, according to a review of 38 retailers by returns manager Narvar.
  • Returns for medium, large, and extra-large items are rising the fastest, according to Impact Analytics, as GLP-1 users cycle through multiple sizes while their bodies change — sometimes dropping a full size every few weeks at peak weight loss.
  • Retailers are responding with higher restocking fees (one doubling its fee to 20%), stricter size chart guidance, and smaller-size inventory increases — but the structural problem is growing as GLP-1s become cheaper and more accessible via pill form.

What Happened?

America’s apparel retailers are grappling with a new source of margin pressure: the mass adoption of GLP-1 weight-loss medications. At peak weight loss, users of drugs like Zepbound can drop a full clothing size every month, and they’re responding by ordering multiple sizes simultaneously and returning what doesn’t fit. Online budget suit retailer FlexSuits has seen a 50% increase in returns over the past year, with founder Farnam Elyasof flagging multi-size orders as a “red flag.” The problem is particularly acute in mid-range sizes: returns for medium, large, and XL items are rising fastest, per Impact Analytics, as GLP-1 users shop while uncertain about where their bodies will land.

Why It Matters?

Returns are among the most destructive forces in retail economics. Shipping, labor, and warehousing costs compound quickly, and out-of-season items returned after their selling window must be marked down. For a $1 billion apparel company with a typical 20% return rate, a 5-to-10 percentage point increase in returns can wipe $20 million off gross margins. The GLP-1 return wave isn’t a blip — it’s structural. An estimated 60% of returns at one women’s brand now cite “item too big” or weight loss as the reason, up from 30-40% a year ago. As GLP-1s become cheaper and expand to a pill form, the user base — and the return rate — will likely grow further. Retailers from Levi Strauss to Costco and Walmart are all actively studying the shift.

What’s Next?

Retailers are adapting on multiple fronts: higher restocking fees (one retailer doubled its fee to 20% of purchase price), more detailed size guidance, and shifts in inventory mix toward smaller sizes. Some are applying stricter return policies to reduce “bracket buying” — ordering multiple sizes with intent to return. But the fundamental challenge remains: a consumer base in active physical transition is inherently difficult to serve with fixed-size merchandise. As GLP-1 adoption widens, the retailers best positioned will likely be those with strong loyalty data, flexible return economics, or direct-to-consumer models where they can engage customers through their weight-loss journey rather than just at the point of purchase.

Source: The Wall Street Journal

Previous Post

Trump Officials Are Feuding Over Whether a Policy Loophole Let China Buy Nvidia’s Most Advanced AI Chips

Next Post

Apple’s Bet on AI Supremacy Starts With Finally Fixing Siri — Using Google’s Technology

Recommended For You

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
2 weeks ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
3 weeks ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
3 weeks ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
4 weeks ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
1 month ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
1 month ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
1 month ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
1 month ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
2 months ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
2 months ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more
Next Post
Apple Store shop front

Apple's Bet on AI Supremacy Starts With Finally Fixing Siri — Using Google's Technology

Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic Calls for a Global Pause in Frontier AI Development, Warning of 'Recursive Self-Improvement' Risk

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI Missed Its User and Revenue Targets — and Its CFO Is Worried About Paying for $600B in Data Center Commitments

April 28, 2026
Google’s Bold AI Bet: Transforming Healthcare After Costly Missteps

Google Gemini Launches ChatGPT Import Tool as AI Assistants Battle for User Lock-In

March 27, 2026
a car is on display in a showroom

Porsche Faces Market Headwinds as China Sales Plunge 28%, Global Deliveries Dip 3%

January 13, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018